20/20 BioLabs meets with East Asia partners to explore expansion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
July 27, 2026 4:30 PM EDTManagement Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region
Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases
GAITHERSBURG, Md., July 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (20/20 Biolabs or the Company), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that members of its management team participated in BIO Asia-Taiwan July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul with... More



